AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18420776 — intervention group
Group type: COMPARATOR
Intervention: Viewing control magazine for 30 minutes
Number of subjects: 0
Study 17182297 — intervention group
Group type: COMPARATOR
Intervention: Alendronate 10 mg/day (ALN)
Number of subjects: 1423
Study 17182297 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day (RLX)
Number of subjects: 1423
Study 17182297 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1423
Study 15531679 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc + beta-carotene supplementation
Number of subjects: 170
Study 15531679 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene + zinc supplementation
Number of subjects: 170
Study 15531679 — intervention group
Group type: COMPARATOR
Intervention: Beta-carotene supplementation
Number of subjects: 170
Study 15531679 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 170
Study 11505331 — intervention group
Group type: EXPERIMENTAL
Intervention: STW‐5 (herbal preparation containing bitter candy tuft and other extracts)
Number of subjects: 60
Study 11505331 — intervention group
Group type: EXPERIMENTAL
Intervention: STW‐5‐S (modified preparation without bitter candy tuft)
Number of subjects: 60
Study 11505331 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 11505331 — intervention group
Group type: EXPERIMENTAL
Intervention: STW‐5
Number of subjects: 60
Study 11505331 — intervention group
Group type: EXPERIMENTAL
Intervention: STW‐5‐S
Number of subjects: 60
Study 9598454 — intervention group
Group type: EXPERIMENTAL
Intervention: CGP56697 (artemether/benflumetol)
Number of subjects: 287
Study 9598454 — intervention group
Group type: COMPARATOR
Intervention: P/S (pyrimethamine/sulfadoxine)
Number of subjects: 287
Study 7994892 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoidectomy with ventilation tube insertion
Number of subjects: 222
Study 7994892 — intervention group
Group type: COMPARATOR
Intervention: Ventilation tube insertion alone
Number of subjects: 222
Study 3046633 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (20-40 mg twice a day)
Number of subjects: 0
Study 3046633 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30799474 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi Etchant (ME)
Number of subjects: 0
Study 30799474 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel Conditioner (EC)
Number of subjects: 0
Study 30799474 — intervention group
Group type: EXPERIMENTAL
Intervention: K-etchant GEL (KE)
Number of subjects: 0
Study 30799474 — intervention group
Group type: COMPARATOR
Intervention: Control (CT; AU without conditioner)
Number of subjects: 0
Study 27853946 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-concentration hypochlorous acid (HOCl) nasal irrigation for 8 weeks
Number of subjects: 43
Study 27853946 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline) nasal irrigation for 8 weeks
Number of subjects: 43
Study 25397352 — intervention group
Group type: EXPERIMENTAL
Intervention: ACC (accurate feedback of baseline)
Number of subjects: 9
Study 25397352 — intervention group
Group type: EXPERIMENTAL
Intervention: DEC (deceived feedback, 2% increase above baseline)
Number of subjects: 9
Study 25397352 — intervention group
Group type: COMPARATOR
Intervention: BaseL (baseline performance)
Number of subjects: 9
Study 25124695 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepping Stones Triple P (SSTP)
Number of subjects: 89
Study 25124695 — intervention group
Group type: COMPARATOR
Intervention: EI services as usual
Number of subjects: 89
Study 20491814 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (lateral onlay block grafts)
Number of subjects: 35
Study 20491814 — intervention group
Group type: EXPERIMENTAL
Intervention: Group D (interpositional bone blocks after LeFort I operation)
Number of subjects: 35
Study 20491814 — intervention group
Group type: COMPARATOR
Intervention: Group E (control, no bone augmentation)
Number of subjects: 35
Study 18368011 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearing gloves
Number of subjects: 44
Study 18368011 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating strawberries
Number of subjects: 44
Study 18368011 — intervention group
Group type: COMPARATOR
Intervention: Control group (no gloves)
Number of subjects: 44
Study 17489080 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumferential sequential gradient compression (CSG)
Number of subjects: 12
Study 17489080 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior uniform compression device (PU)
Number of subjects: 12
Study 17489080 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior sequential rapid gradient inflation device (PSR)
Number of subjects: 12
Study 16301230 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 2 mug/kg
Number of subjects: 169
Study 12394199 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt tablets (approximately 700 mg/h of sodium)
Number of subjects: 38
Study 9839775 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep-deprived EEG
Number of subjects: 46
Study 9839775 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted ambulatory EEG
Number of subjects: 46
Study 7816993 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized training at the ventilatory threshold level, walking four times a week at the heart rate corresponding to the metabolic level of ventilatory threshold.
Number of subjects: 20
Study 7816993 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 20
Study 7816993 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized training at the ventilatory threshold level.
Number of subjects: 20
Study 2915315 — intervention group
Group type: EXPERIMENTAL
Intervention: Single goniotomy
Number of subjects: 7
Study 2915315 — intervention group
Group type: COMPARATOR
Intervention: Two simultaneous goniotomies
Number of subjects: 7
Study 2915315 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of Sodium hyaluronate (Healon)
Number of subjects: 7
Study 31680011 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin for five days
Number of subjects: 150
Study 31680011 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin
Number of subjects: 150
Study 31680011 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 31524133 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural Activation (BA) therapy, up to 15 sessions over 4 months.
Number of subjects: 48
Study 31524133 — intervention group
Group type: COMPARATOR
Intervention: Usual stroke care (control group).
Number of subjects: 48
Study 31524133 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural Activation (BA) therapy.
Number of subjects: 48
Study 28578470 — intervention group
Group type: EXPERIMENTAL
Intervention: Below-elbow cast (BEC)
Number of subjects: 72
Study 28578470 — intervention group
Group type: COMPARATOR
Intervention: Above-elbow cast (AEC)
Number of subjects: 72
Study 26109257 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncooked corn starch (CS)
Number of subjects: 5
Study 26109257 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified corn starch (MCS)
Number of subjects: 5
Study 26109257 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasta meal
Number of subjects: 5
Study 24215565 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemisinin-naphthoquine (ANQ) - total target dose of 24.5 mg/kg (naphthoquine 7 mg/kg and artemisinin 17.5 mg/kg), once a day for three days
Number of subjects: 0
Study 24215565 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine-primaquine (CQ-PQ) - total CQ dose of 24 mg base/kg, once a day for three days plus PQ dose of 0.45 mg base/kg/day, once a day for eight days
Number of subjects: 0
Study 24215565 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemisinin-naphthoquine (ANQ)
Number of subjects: 0
Study 24215565 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine-primaquine (CQ-PQ)
Number of subjects: 0
Study 21365002 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART
Number of subjects: 60
Study 21365002 — intervention group
Group type: COMPARATOR
Intervention: Control (HIV-seronegative subjects)
Number of subjects: 60
Study 18226746 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 16549227 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 3mg/kg
Number of subjects: 18
Study 16549227 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 5mg/kg
Number of subjects: 18
Study 16549227 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 12657908 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 0
Study 12657908 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pharmacokinetic monitoring (CPM) of MMF
Number of subjects: 0
Study 11049921 — intervention group
Group type: EXPERIMENTAL
Intervention: Face mask ventilation (FM)
Number of subjects: 10
Study 11049921 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngoscope‐guided orotracheal intubation (OETT)
Number of subjects: 10
Study 11049921 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophageal tracheal Combitube insertion (ETC)
Number of subjects: 10
Study 11049921 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubating laryngeal mask insertion with fiberscope‐guided tracheal intubation (ILM‐OETT)
Number of subjects: 10
Study 11049921 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway insertion (LMA)
Number of subjects: 10
Study 11049921 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum head‐neck flexion (FLEX‐MAX)
Number of subjects: 10
Study 11049921 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum head‐neck extension (EXT‐MAX)
Number of subjects: 10
Study 11049921 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiberscope‐guided nasal intubation (FOS‐NETT)
Number of subjects: 10
Study 11049921 — intervention group
Group type: COMPARATOR
Intervention: FLEX‐MAX
Number of subjects: 10
Study 10164145 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary interventions based on randomised controlled trials or systematic reviews
Number of subjects: 40
Study 1449620 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy regimens
Number of subjects: 0
Study 1449620 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple chemotherapy regimens
Number of subjects: 0
Study 1449620 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy regimens
Number of subjects: 0
Study 1449620 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow transplantation (autologous or allogeneic)
Number of subjects: 0
Study 1449620 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental methods (biologic and immune response modifiers)
Number of subjects: 0
Study 3883261 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical estimation of fetal weight
Number of subjects: 62
Study 3883261 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonographic methods
Number of subjects: 62
Study 3883261 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression equation using ultrasonically measured fetal abdominal circumference
Number of subjects: 62
Study 3883261 — intervention group
Group type: EXPERIMENTAL
Intervention: All three methods of estimating fetal weight
Number of subjects: 62
Study 31960409 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal transfusion thresholds (105 g/l, maintaining 110-125 g/l)
Number of subjects: 38
Study 31960409 — intervention group
Group type: COMPARATOR
Intervention: Restrictive transfusion thresholds (80 g/l, to maintain haemoglobin 85-100 g/l)
Number of subjects: 38
Study 30575473 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Number of subjects: 695
Study 30575473 — intervention group
Group type: COMPARATOR
Intervention: Watchful Waiting
Number of subjects: 695
Study 27455842 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg peri-articular TXA
Number of subjects: 60
Study 27455842 — intervention group
Group type: COMPARATOR
Intervention: 750 mg IV TXA
Number of subjects: 60
Study 24917354 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume, high-intensity aerobic interval training (HAIT), 18 min, 180 kcal per session
Number of subjects: 24
Study 24917354 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume, high-intensity aerobic interval training (HAIT)
Number of subjects: 24
Study 24917354 — intervention group
Group type: COMPARATOR
Intervention: High-volume, moderate-intensity continuous aerobic training (CAT), 45 min, 360 kcal per session
Number of subjects: 24
Study 24917354 — intervention group
Group type: COMPARATOR
Intervention: High-volume, moderate-intensity continuous aerobic training (CAT)
Number of subjects: 24
Study 23289194 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg daily)
Number of subjects: 14
Study 23289194 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate (400 mg daily)
Number of subjects: 14
Study 23289194 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Simvastatin and Bezafibrate
Number of subjects: 14
Study 23289194 — intervention group
Group type: COMPARATOR
Intervention: Non-diabetic control subjects
Number of subjects: 14
Study 20394879 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 1595
Study 20394879 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 1595
Study 18715206 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine (Lantus)
Number of subjects: 60
Study 18715206 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glulisine (Apidra)
Number of subjects: 60
Study 15741724 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% (w/v) sucrose plus 70 microg Fe/ml
Number of subjects: 16
Study 15741724 — intervention group
Group type: COMPARATOR
Intervention: 20% (w/v) sucrose
Number of subjects: 16
Study 15741724 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% (w/v) sucrose plus 18 microg Fe/ml
Number of subjects: 16
Study 15741724 — intervention group
Group type: COMPARATOR
Intervention: water
Number of subjects: 16
Study 14651815 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical and statistical review group
Number of subjects: 43
Study 14651815 — intervention group
Group type: COMPARATOR
Intervention: Clinical review group
Number of subjects: 43
Study 10800070 — intervention group
Group type: EXPERIMENTAL
Intervention: CD34+ cell dose greater than 5 x 106/kg
Number of subjects: 28
Study 10800070 — intervention group
Group type: EXPERIMENTAL
Intervention: CD34+ cell dose higher than 5 x 106/kg
Number of subjects: 28
Study 10800070 — intervention group
Group type: COMPARATOR
Intervention: CD34+ cell dose lower than 5 x 106/kg
Number of subjects: 28
Study 8695127 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 54
Study 8695127 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 1476283 — intervention group
Group type: COMPARATOR
Intervention: 4% albumin (up to 21)
Number of subjects: 16
Study 1476283 — intervention group
Group type: EXPERIMENTAL
Intervention: Elohes (1.51)
Number of subjects: 16
Study 1476283 — intervention group
Group type: EXPERIMENTAL
Intervention: Elohes and albumin
Number of subjects: 16
Study 6330875 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg)
Number of subjects: 17
Study 6330875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 30733025 — intervention group
Group type: EXPERIMENTAL
Intervention: Adductor Canal Nerve Blockade (ACB)
Number of subjects: 90
Study 30733025 — intervention group
Group type: COMPARATOR
Intervention: Femoral Nerve Blockade (FNB)
Number of subjects: 90
Study 30419828 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk lifestyle class (14.4%)
Number of subjects: 750
Study 30419828 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate-risk lifestyle class (54.6%)
Number of subjects: 750
Study 30419828 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk lifestyle class (31%)
Number of subjects: 750
Study 30419828 — intervention group
Group type: COMPARATOR
Intervention: Age increase
Number of subjects: 750
Study 30419828 — intervention group
Group type: COMPARATOR
Intervention: Marital status (widowed or divorced)
Number of subjects: 750
Study 30419828 — intervention group
Group type: COMPARATOR
Intervention: Higher education level
Number of subjects: 750
Study 27653564 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal high-flow therapy
Number of subjects: 564
Study 27653564 — intervention group
Group type: COMPARATOR
Intervention: Nasal CPAP
Number of subjects: 564
Study 27858768 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic and strengthening exercise
Number of subjects: 14
Study 20843512 — intervention group
Group type: EXPERIMENTAL
Intervention: CoolGard 3000™ system and Icy™ catheter
Number of subjects: 7
Study 20843512 — intervention group
Group type: COMPARATOR
Intervention: Historical control group
Number of subjects: 7
Study 19855988 — intervention group
Group type: EXPERIMENTAL
Intervention: SabreSource image guidance system
Number of subjects: 20
Study 19855988 — intervention group
Group type: COMPARATOR
Intervention: Fluoroscopy-guided thermal ablation therapy
Number of subjects: 20
Study 16934334 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 437
Study 16934334 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 437
Study 16934334 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-suicidal)
Number of subjects: 437
Study 16934334 — intervention group
Group type: EXPERIMENTAL
Intervention: Resolved suicidality
Number of subjects: 437
Study 16934334 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergent and persistent suicidality
Number of subjects: 437
Study 16401533 — intervention group
Group type: EXPERIMENTAL
Intervention: Physio ring (n = 43)
Number of subjects: 96
Study 16401533 — intervention group
Group type: COMPARATOR
Intervention: Classic ring (n = 53)
Number of subjects: 96
Study 16401533 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 96
Study 12437255 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised training using a VR simulator
Number of subjects: 21
Study 12437255 — intervention group
Group type: COMPARATOR
Intervention: Control group (no further training)
Number of subjects: 21
Study 10759736 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreaticogastrostomy (PG)
Number of subjects: 142
Study 10759736 — intervention group
Group type: COMPARATOR
Intervention: Pancreaticojejunostomy (PJ)
Number of subjects: 142
Study 8712826 — intervention group
Group type: EXPERIMENTAL
Intervention: MMC (4 mg, twice a week, total 1 mg/kg) + OK-432 (or PSK)
Number of subjects: 185
Study 8712826 — intervention group
Group type: EXPERIMENTAL
Intervention: MMC + OK-432 + HCFU (600 mg, per day)
Number of subjects: 185
Study 1559386 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol (TIM)
Number of subjects: 20
Study 1559386 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol (BET)
Number of subjects: 20
Study 1559386 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 20
Study 4035328 — intervention group
Group type: EXPERIMENTAL
Intervention: sn‐polyenylphosphatidylcholin (PPC) 450 mg b.i.d. (three times daily)
Number of subjects: 27
Study 4035328 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 4035328 — intervention group
Group type: EXPERIMENTAL
Intervention: sn‐polyenylphosphatidylcholin (PPC)
Number of subjects: 27
Study 30826585 — intervention group
Group type: EXPERIMENTAL
Intervention: Unconditional cash transfer program
Number of subjects: 0
Study 30232708 — intervention group
Group type: EXPERIMENTAL
Intervention: Calgranulin A high expression
Number of subjects: 158
Study 30232708 — intervention group
Group type: EXPERIMENTAL
Intervention: Calgranulin A low expression
Number of subjects: 158
Study 25945816 — intervention group
Group type: EXPERIMENTAL
Intervention: Practicing under desirable difficulty conditions
Number of subjects: 0
Study 25945816 — intervention group
Group type: COMPARATOR
Intervention: Control condition with predefined random order for difficulty levels
Number of subjects: 0
Study 24285336 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised walking (60 min three times weekly for 3 months)
Number of subjects: 78
Study 24285336 — intervention group
Group type: COMPARATOR
Intervention: Standard care for physical activity and weight reduction
Number of subjects: 78
Study 22465641 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon kyphoplasty
Number of subjects: 3
Study 22465641 — intervention group
Group type: COMPARATOR
Intervention: Vertebroplasty
Number of subjects: 3
Study 22465641 — intervention group
Group type: EXPERIMENTAL
Intervention: Shield kyphoplasty
Number of subjects: 3
Study 20122451 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled β2-agonists (formoterol, salbutamol, salmeterol, terbutaline)
Number of subjects: 0
Study 20122451 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 17633360 — intervention group
Group type: EXPERIMENTAL
Intervention: Feiji Recipe (FJR)
Number of subjects: 60
Study 16075346 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryopreserved cadaver femoral vein allografts (SYN)
Number of subjects: 54
Study 16075346 — intervention group
Group type: COMPARATOR
Intervention: Polytetrafluoroethylene (PTFE) grafts
Number of subjects: 54
Study 12153065 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered history questionnaire
Number of subjects: 241
Study 12153065 — intervention group
Group type: COMPARATOR
Intervention: Control group (no history questionnaire)
Number of subjects: 241
Study 10420815 — intervention group
Group type: COMPARATOR
Intervention: Interferon-alpha
Number of subjects: 0
Study 10420815 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant chemotherapy
Number of subjects: 0
Study 8928582 — intervention group
Group type: EXPERIMENTAL
Intervention: ATS (autotransfusion system)
Number of subjects: 82
Study 8928582 — intervention group
Group type: COMPARATOR
Intervention: nonATS (no autotransfusion system)
Number of subjects: 82
Study 1979796 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine (5 to 20 mg once daily)
Number of subjects: 0
Study 1979796 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine (25 to 75 mg/day in divided doses)
Number of subjects: 0
Study 1979796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0